Meeting
2022 ASCO Annual Meeting
Phase 1 study of KT-413, a targeted protein degrader, in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Authors
Don A. Stevens
Louisville Onc, Louisville, KY
Don A. Stevens , Reginald Ewesuedo , Alice McDonald , Sagar Agarwal , Patrick Henrick , Rachelle Perea , Ashwin Gollerkeri , Jared Gollob
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Clinical Trial Registration Number
NCT05233033
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS3170)
DOI
10.1200/JCO.2022.40.16_suppl.TPS3170
Abstract #
TPS3170
Poster Bd #
152a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
CRC-403: A phase 1/2 study of bbT369, a dual targeting CAR T-cell drug product with a gene edit, in relapsed and/or refractory B-cell non-Hodgkin lymphoma (NHL).
First Author: Frederick L. Locke
Poster
2022 ASCO Annual Meeting
Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies.
First Author: Erel Joffe
Poster
2016 ASCO Annual Meeting
Phase 2 multi-center study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).
First Author: Franck Morschhauser
Poster
2024 ASCO Annual Meeting
Phase I study of CN201, a novel CD3xCD19 bispecific antibody, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
First Author: Yang Xie